By: Melissa Freeman, MD, PGY1
For over a decade now, statins, or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, have facilitated millions of patients in the management of their atherosclerosis. Statins are known for their ability to reduce hepatic lipoproteins, up-regulate hepatic …
Coming right on the heels of the recent warning from the FDA about the risk of fractures and Rosiglitazone, the FDA announced on March 9th that pioglitazone (Actos) has also been linked to an increased occurrence of arm, hand, and foot fractures among …
Commentary By: Christopher Johnson, MSIV and Glenn Matfin, MD Clinical Associate Professor of Medicine, Divsion of Endocrinology
When was the last time you had a diabetic patient in clinic whose hemoglobin A1C was elevated, prompting you to modify their diabetic regimen? …
Commentary By: Cara Litvin PGY-3
The FDA recently informed physicians of a report issued by GlaxoSmithKline acknowledging that Avandia (rosiglitazone) has been linked to increased fractures in females (1). The report stems from a review of the safety data from ADOPT (A Diabetes …
Commentary By Josh Remick, PGY-2
In the December 27th 2006 issue of JAMA, Yang et al. reported the results of a nested case-control study of United Kingdom patients entitled “Long-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture.” …
A 53 year old male with chronic hepatitis C and type 2 diabetes is found to have a moderately elevated cholesterol.
1. Is it safe to start a statin?
2. Do statins have any effect on viral replication?
Comentary By Ed Bini, M.D. …
56 year old Hispanic female with a history of hypertension, type 2 diabetes on oral medications, hyperlipidemia and normal renal function. Over the past 2 years she has been noted to have …
Low HDL is a well known independent risk factor for atherosclerotic disease. As a result, there have been several attempts to develop medications to raise HDL. Specific targets include the inhibition of cholesteryl ester transfer protein, which …